Cancer Treatment

Through the eyes of a cancer carer - Cootamundra Herald
( Thu, 11 Mar 2010 20:39:39 GMT+00:00 )

Through the eyes of a cancer carer
Cootamundra Herald
Mrs Smith cared for her late husband and supported him through chemotherapy treatment for close to five years after he was diagnosed with lung cancer in ...

Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R ... - FOXBusiness
( Thu, 11 Mar 2010 21:28:59 GMT+00:00 )

Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R ...
FOXBusiness
Palliative treatment helps to relieve symptoms associated with advanced prostate cancer. Lupron Depot works by suppressing the production of the hormone ...

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ... - Trading Markets (press release)
( Thu, 11 Mar 2010 21:24:42 GMT+00:00 )

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ...
Trading Markets (press release)
Developed by Debiopharm Group and first approved in the US in 2000, TRELSTAR(R) is indicated for the palliative treatment of advanced prostate cancer and is ...

Neoprobe to Hold Lymphoseek Update Call - dBusinessNews Cincinnati (press release)
( Thu, 11 Mar 2010 20:33:45 GMT+00:00 )

Neoprobe to Hold Lymphoseek Update Call
dBusinessNews Cincinnati (press release)
... treatment needs of patients. Neoprobe currently markets the neoprobe GDS line of gamma detection systems that are widely used by cancer surgeons. ...

and more »

Benefit Not Seen From Adding Sorafenib in Lung Cancer NSCLC study patients ... - ModernMedicine
( Thu, 11 Mar 2010 20:51:14 GMT+00:00 )

ModernMedicine

Benefit Not Seen From Adding Sorafenib in Lung Cancer NSCLC study patients ...
ModernMedicine
Patients with squamous cell carcinoma in the treatment group had shorter median overall survival than patients in the placebo group (8.9 versus 13.6 months) ...

Philips slides amid talk of Hologic bid - Financial Times
( Thu, 11 Mar 2010 20:44:03 GMT+00:00 )

Philips slides amid talk of Hologic bid
Financial Times
... is a leading manufacturer of diagnostic and surgical equipment, including breast cancer treatment and cervical cancer screening. ...

and more »

Synta Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Financial Results - PharmaLive.com (press release)
( Thu, 11 Mar 2010 20:39:13 GMT+00:00 )

Synta Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Financial Results
PharmaLive.com (press release)
Identified that elesclomol exerts its anti-cancer activity by disrupting cancer cell mitochondrial metabolism, and that this activity requires normal oxygen ...

and more »

Caraco gets FDA approval for generic Eloxatin - IdahoStatesman.com
( Thu, 11 Mar 2010 21:06:55 GMT+00:00 )

Caraco gets FDA approval for generic Eloxatin
IdahoStatesman.com
- AP DETROIT Caraco Pharmaceutical Laboratories Ltd. said Thursday it launched a generic version of Sanofi-Aventis' cancer treatment Eloxatin. ...

and more »

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ... - MarketWatch (press release)
( Thu, 11 Mar 2010 21:21:34 GMT+00:00 )

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ...
MarketWatch (press release)
Developed by Debiopharm Group and first approved in the US in 2000, TRELSTAR(R) is indicated for the palliative treatment of advanced prostate cancer and is ...

GenVec Reports Fourth Quarter and 2009 Year-End Financial Results - MSN Money
( Thu, 11 Mar 2010 21:12:26 GMT+00:00 )

GenVec Reports Fourth Quarter and 2009 Year-End Financial Results
MSN Money
... 1.15]) We announced that the US Food and Drug Administration (FDA) granted orphan drug designation to TNFerade for the treatment of pancreatic cancer. ...

and more »

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ... - Earthtimes (press release)
( Thu, 11 Mar 2010 21:15:28 GMT+00:00 )

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ...
Earthtimes (press release)
Developed by Debiopharm Group and first approved in the US in 2000, TRELSTAR is indicated for the palliative treatment of advanced prostate cancer and is ...

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ... - CNNMoney.com (press release)
( Thu, 11 Mar 2010 21:21:02 GMT+00:00 )

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ...
CNNMoney.com (press release)
Developed by Debiopharm Group and first approved in the US in 2000, TRELSTAR is indicated for the palliative treatment of advanced prostate cancer and is ...

Social Security to Provide Helpful Health Care Information to Over 3 Million ... - eNews Park Forest
( Thu, 11 Mar 2010 21:28:03 GMT+00:00 )

Social Security to Provide Helpful Health Care Information to Over 3 Million ...
eNews Park Forest
For example, an applicant with breast cancer, rheumatoid arthritis, Alzheimer's disease, diabetes, or other diseases can go to the site to gather ...

See the change - Mumbai Mirror
( Thu, 11 Mar 2010 20:44:06 GMT+00:00 )

Mumbai Mirror

See the change
Mumbai Mirror
In 2003/04, I was detected with intestinal cancer. It was a setback with my glaucoma treatment already underway. I decided to tackle it head on and began ...

and more »

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ... - Your-Story.org (press release)
( Thu, 11 Mar 2010 21:23:49 GMT+00:00 )

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month ...
Your-Story.org (press release)
Developed by Debiopharm Group and first approved in the US in 2000, TRELSTAR is indicated for the palliative treatment of advanced prostate cancer and is ...

FDA approval for generic cancer drug - WLFI.com
( Thu, 11 Mar 2010 21:21:40 GMT+00:00 )

FDA approval for generic cancer drug
WLFI.com
DETROIT (AP) - Caraco Pharmaceutical Laboratories Ltd. said Thursday it launched a generic version of Sanofi-Aventis' cancer treatment Eloxatin. ...

Complete the Form Below
and Unlock Your
Mobile Phone instantly!

Name

Email

Mobile/Cell Phone

How did you find us

listtopguide.info		Home Contact Us